univers coverag
calendar event
medacorp event post-op pain investor dinner discuss kol
pacira exparel heron new york
medic meet american societi healthcar engin american societi
virolog american veterinari medic associ societi studi ingest
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
bone pick medacorp survey suggest solid crysvita adopt esp
ped
 methodolog dcf analysi discount rate termin growth
bottom line gain better understand crysvita launch commiss survey
medacorp specialist treat patient x-link hypophosphatemia xlh survey
physician posit view crysvita expect use extens among pediatr
pt market benefit adult xlh rais revenu
estim us slightli put us line consensu although like variabl
street model crysvita due complex econom partner kyowa
hakko kirin khk link meanwhil lower eu/latin america project due lower
degre visibl tougher commerci environ discuss companion report
publish today also ad model rais price
assumpt believ investor appreci crysvita may continu grow
year ultragenyx advanc gene therapi program acquir dmtx acquisit link
link togeth increas pt reiter outperform
crysvita uptak could support demand among nephrologist intrigu find treat
half xlh patient survey well endocrinologist discuss target
crysvita address unmet medic need among xlh pt
specialist view crysvita better oral phosphate/vitamin although cost rel modest
benefit oral phosphate/vit may headwind
updat model
gene therapi program glycogen storag diseas could sweeten
analysi discount rate termin growth
bottom line ultragenyx second gene therapi program glycogen storag diseas
type acquir dimens link link could provid upsid believ
order gain better understand program expect report first data
took closer look preclin data spoke medacorp kol ultragenyx
result literatur search convers introduc revenu model project
peak sale risk adjust probabl success also rais
estim price ornithin transcarbamylase/otc defici eu
per patient eu previous appli luxturna/hemophilia price framework
link current cost ravicti indic crysvita revenu estim also increas
due posit medacorp survey publish today link togeth rais pt
reiter outperform
lengthen time hypoglycem event goal pt defici
phosphat enzym lead signific recurr hypoglycemia event untreat
preclin data mice encourag
amount activ key fast toler
data cohort
model conserv could still signific product
risk/reward increasingli attract execut still pt
 methodolog ev/sal multipl sale estim
bottom line defend share sell-off last week -- view
reaction tent rule patent infring suit op departur
vice-president sale -- believ stock close bear case scenario morn
pre-announce result lower sale guidanc
impli y/i growth back half year y/i full year mid-
point acknowledg given execut issu past month manag
penalti box also believ stori remain intact fundament
perspect spinal cord stimul sustain double-digit growth market
forese futur acceler possibl new indic come on-line
view highli differenti product view still best-in-
class clinic data support argu share complet reach trough
level acknowledg share volatil reason even outsid patent
infring suit op -- least includ inconsist quarter rel
expect -- volatil like continu clariti possibl outcom
think risk/reward much favor -- downsid share
upsid potenti link -- current level repres attract entri point start
build ad posit
reiter op pt
outlook move lower take conserv view given lack visibl
busi updat search new vice-president sale underway litig on-going
revenu mm dilut gaap ep
bottom line today publish quarterli preview larg cap biopharma
compani coverag typic strongest quarter year oper
biopharmaceut compani sequenti growth prior quarter largest
associ increas guidanc potenti revers sentiment quarter
year howev believ year consensu alreadi captur expect
opportun sinc tradit per-quart adjust mani case
line current consensu estim larg cap biotech coverag
benefit addit ship day compar last year day compar last
quarter could boost revenu respect compar per day demand
opposit price increas definit moder year especi spars
controversi mid-year mean channel inventori may recov low
boost usual level currenc tailwind support ex-
us product sale also significantli diminish quarter
mean report growth ou product sale depend hedg could
significantli lower
revenu mm dilut ep includ option expens present
revenu mm ep exclud option expens
revenu million dilut non-gaap ep
revenu ep exclud option expens estim pro forma spin
revenu million ep exclud option expens
revenu mm non-gaap ep ex stock option expens
revenu mm dilut ep non-gaap
ftc grant anti-trust clearanc verscend/verita acquisit
bottom line expect ftc grant anti-trust clearanc verscend/verita acquisit
cotv larg expect multipl vendor provid similar servic
market remain highli competit particularli retrospect payment integr
analysi discount rate termin valu
preview gener pain women anti-infect
 methodolog ep growth impli price-to-earnings
ep cash
better time around valid platform poc come initi op
wacc lt growth rate
believ investor expect head ph data readout
low especi sinc lack clariti around requir approv
still discuss fda around data analysi plan studi
niemann-pick type np-c ultra-rar progress neurodegen genet
diseas occur bodi properli break cholesterol lipid
lead harm amount lipid accumul spleen liver brain
believ ph i/ii result encourag given breakthrough
statu drug fda prior comment bar approv like low
medacorp specialist spoke enthusiast current
treatment altern off-label use miglustat limit efficaci high ae
rate diarrhea abdomin pain nausea
forecast sale grow larg opportun
believ one sever pipelin asset critic offset
declin key franchis acthar inomax ofirmev face competit
come year posit regulatori execut increas investor
interest emerg pipelin
one regn import catalyst approv antibodi cemiplimab
cutan squamou cell carcinoma cscc
compani pdufa date octob research suggest first approv
checkpoint antibodi new indic typic come ahead pdufa date like
june juli cemiplimab estim
particularli true applic benefit breakthrough design
prioriti review case cemiplimab
regeneron also appear signal expect approv occur earlier
date confirm us commerci team readi launch product
immedi avail channel
project peak pos-adjust us cemiplimab sale
note ph criteria differ nccn guidelin meant trial
result directli compar prior studi
discuss fda on-going primari endpoint determin
told endpoint may similar select ph design
link note
recent pamrevlumab result suggest convent ct scan may accur predict
resect lapc patient
success pamrevlumab neoadjuv set may depend chang resctabl
standard adopt clinic regulatori commerci endpoint
late august omadacyclin antibiot skin pneumonia adcom
key catalyst remain time-frame conven adcom potenti
aug time-frame potenti approv oct time-frame could move
view fda decis panel indic concern
link view panel public forum review posit risk/
benefit profil omadacyclin evidenc last nce antibiot pneumonia
sinc adcom conven
continu view data packag omadacyclin support approv
believ current level street underappreci valu omadacyclin
gain clariti key discuss topic brief document
releas publicli two busi day ahead adcom date
pdufa date expect octob
augment trial approach complet top-lin result releas
trial studi cytotoxic-fre combin revlimid rituximab
would attract altern cytotox standard-of-car fl
degre upsid limit time like approv adopt
reimburs indic expect generic revlimid
believ data present american psychiatr associ confer
provid limit insight genesight endpoint
view test key mygn long-term top-lin growth potenti
drive revenu upsid reimburs mygn desir
current medicar rate
signific controversi alreadi surround reach potenti given
pt trial fail meet primari endpoint met secondari endpoint remiss
respons data may provid sub-
analysi patient fail chang view medacorp specialist payer
journal public expect june coverage/contract decis expect
announc beyond
link takeaway meet manag
sourc leerink research compani inform factset price prior day
medcac panel procedur volum requir hospit heart team
member begin maintain transcathet aortic valv replac ew
fda adcom joint meet drug safeti risk manag anesthet
fda adcom antimicrobi drug omadacyclin acut bacteri skin skin
structur infect absssi community-acquir bacteri pneumonia cabp
medcac panel t-cell therapi
pdufa teva fremanezumab cgrp migrain
fda adcom vaccin relat biolog product
pdufa dupix moder sever asthma adult adolesc
pdufa xyrem cataplexi excess daytim sleepi
pdufa revefanacin lama copd
pdufa bremelanotid hypoact sexual desir disord fda adcom
schedul
american societi virolog
american societi healthcar engin
societi studi ingest behavior
intern societi thrombosi haemostasi
breast surgeri bodi contour symposium
american societi retina specialist
societi neurointervent surgeri
american associ physicist medicin
american associ clinic chemistri
world congress cancer skin
european societi cardiolog esc
associ offici analyt chemist aoac
societi laparoendoscop surgeon minim invas surgeri week
intern network fatti acid oxid research manag
world congress pharmaci pharmaceut scienc fip
societi studi inborn metabol diseas ssiem symposium
bioprocess intern confer exhibit
advanc genom biolog technolog agbt precis meet
societi minim invas spine surgeri smiss annual forum
american societi hypertens joint w/ american heart associ aha
european migran headach trust intern congress ehmtic
american academi otolaryngolog head neck surgeri aao-hnsf
intern societi research iser biennial meet
intern associ studi pain iasp world congress pain
european academi dermatolog venereolog eadv
american societi surgeri hand assh
advanc genom biolog technolog agbt precis meet
associ vascular access annual scientif meet
heart failur societi america hfsa annual scientif meet
go live az
model rarehav recent updat pleas contact
leerink repres wish review model
medic suppli devic individu co preview cardio large-cap
biopharma preview gener pain women anti-infect
 takeaway immuno-oncolog panel
 takeaway nash panel
biopharma lp hic takeaway ibd panel
 takeaway migrain panel
biopharma lp hic reimburs panel oncolog gene therapi target limit
 rova-t present show anoth rout failur experiment oncolog
adap -- flash manag convers highlight data pipelin progress
adap studi advanc cell dose posit safeti data pt
-- flash present highlight opportun colorect cancer
celg updat strengthen profil remark respons durabl
celg profil continu present outperform
 tazemetostat mesothelioma data opportun combin outperform
 success pamrevlumab lapc may depend endpoint paradigm shift
imdz -- flash event highlight imdz approach strategi outperform
 event highlight investig view forward ii data outperform
-- flash highlight encourag data biomark strategi gastric
-- flash updat demonstr continu safeti earli efficaci
-- flash aducanumab phase trial expand variabl endpt requir
 growth margin management stabil still lack pipelin catalyst market
 ctad medacorp call aducanumab abeta hypothesi
biopharma biopharma catalyst tracker import catalyst remain second half
 takeaway annual day
 biotech portfolio concentr explain multipl compress
 first apprais tax offer small benefit
 vertex alexion top pick
-- flash takeaway leerink day outperform
 eas data confirm durabl gocovri superior vs gener
 day preview late stage program turn launch mani
 takeaway annual day
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
 growth deal capac target market
biopharma praluent show mortal benefit lower take aim highest risk group
mdco -- flash inclisiran lesson fourier/odyssey may better
novob dc highlight nvo management roundtabl discuss boston market
medic devic ada dash make splash highlight recent
medic devic leerink healthcar confer panel devic penetr set
medic devic leerink leadership seri outset drive shift dialysi self-car
novob dc highlight nvo management roundtabl boston market perform
medic devic leerink healthcar confer panel devic penetr set
medic suppli devic initi takeaway sage robot continu gain
medic devic survey support market share re-gain assumpt
medic devices-cardiolog hr takeaway cabana unlik chang af practic
biopharma price right payer fail get drug class come
 stabil sell-sid price trend medic posit ug op outperform
hcit distribut fda take step improv competit distributor near trough
 acthar survey suggest faster eros payer pressur competitor entri
qure updat model higher price assumpt po pt
 price commerci updat fda approv burosumab/crysvita
 respit price yet friendli hill fda could
biopharma trump-azar puls call drug price blueprint limit current hh
 hemophilia price adjust reflect efficaci luxturna paradigm pt
 outlook move higher price clariti suggest possibl upsid pt
hcit distribut blueprint thorough pbm like abl manag rebat
hcit distribut outlin possibl drug price polici draconian
fear
 updat hemophilia price assumpt ad pomp program pt
adap kol address controversi ahead multipl data readout outperform
 anoth setback ido outperform ideal combo still unclear
biopharma what immuno-oncolog takeaway
biopharma summari leerink immuno-oncolog roundtabl
celg anoth bet car-t probabl probabl sensibl even
 deep dive highlight oncolog focu strategi nash market perform
 highlight kol panel lung cancer io cell
celg anoth bet car-t probabl probabl sensibl even
 patent strategi come focu mitig biosimilar risk outpfrm outperform
 news patent decis one remind method use patent
 doubl extend patent horizon tecfidera
 investor sleep path ip protect pt
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg dose-respons plenti evid activ otezla uc outperform
celg qed ged late stage failur throw ibd bd strategi
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
hcit distribut -- flash minut stori appear one-sid
achn partnership termin push cfd inhibitor main stage pt
biopharma might deton event look like screen pot match-
 sotp support current stock price where pipelin upsid market
 sotp suggest pipelin free even stock bounc market perform
 dupi miss-inventori demand trend intact partnership flail
biopharma viii partnership acquisit biopharma new top list
ci june ci cfo boston meet insight rais pt outperform
 aet bring comprehens member
dplo mid-mkt pbm acquisit complet strateg move market perform
esrx detail esrx deal term dplo may acquisit target
 evolv provid landscap initi outperform initi
outperform
 partnership valid local jaki gut de-risk develop path pt
 increas pt takeda collabor stock weak offer oppti
manag -- flash gov lose t-twx close without condit posit
pharmaci benefit manag t-twx approv bode pend ci-esrx cvs-
deal capac
 come-back stori make survey support opu market
share assumpt outperform
-- contact leerink repres detail access podcast
 pnh survey-soliri still grow like switch monthli sc best
athn survey highlight slow market time take deal pt market
biopharma atop derm still without ped leerink dupi derm survey
 hiv survey rapid adopt biktarvi challeng outlook
hcit distribut ambulatori survey show slowdown replac market on-going
shift vbc
hcit distribut demand shift analyt effect use
 vyxeo survey suggest outpati usag grow outperform
major medacorp survey lung cancer posit azn
limit upsid link
medic suppli devic survey flu help otherwis normal volume downtick
medic devic survey support market share re-gain assumpt
 acthar survey suggest faster eros payer pressur competitor entri
medic devic survey direct posit mute hope
teva rais austedo sale analysi posit medacorp physician survey
 open ablat atriclip drive near term growth mi longer term
 differenti poc signific runway impli upsid pt
 ceo call focus growth outlook potenti upsid area lrp pt
outlook alpha opportun abound healthcar share
biopharma crash cours kol call highlight busi aml landscap new agent
biopharma highlight heart failur kol discuss
